Presurgical Treatment With Ribociclib and Letrozole in Patients With Locally Advanced Breast Cancer: the NEOLETRIB Study

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 06 Aug 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Letrozole (Primary) ; Ribociclib (Primary) ; Goserelin
Indications Advanced breast cancer; Early breast cancer; HER2 negative breast cancer
Focus Pharmacodynamics
Acronyms NEOLETRIB

02 Aug 2024 Status changed from recruiting to completed.
13 Sep 2022 Results assessing Single cell characterization of longitudinal biopsies from Locally advanced breast cancer patients belonging to the luminal-A and luminal-B subtypes treated with neoadjuvant therapy with ribociclib and letrozole, presented at the 47th European Society for Medical Oncology Congress
21 Jul 2022 Planned initiation date changed from 1 Apr 2022 to 1 Dec 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com